Every Form 4 that Dare Bioscience, Inc. (DARE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DARE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DARE filings page.
Grossman Jessica D. reported acquisition or exercise transactions in this Form 4 filing.
Dare Bioscience director Jessica D. Grossman received an equity grant instead of cash fees for her board service. She was awarded 26,066 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share.
Each restricted stock unit represents a right to receive one Dare Bioscience share when it vests. All 26,066 units vest on January 4, 2027, and this grant brings her directly held position from this award to 26,066 shares.
Kelley Susan L. reported acquisition or exercise transactions in this Form 4 filing.
Dare Bioscience, Inc. reported that director Susan L. Kelley received a grant of 23,696 shares of common stock in the form of restricted stock units (RSUs). These RSUs were granted in lieu of cash compensation for her service on the board and its committees.
Each RSU represents a right to receive one share of Dare Bioscience common stock when vested, and the RSUs vest on January 4, 2027. Following this award, Kelley’s reported direct holdings total 23,696 shares.
Dare Bioscience director Gregory W. Matz received a grant of 30,805 shares of common stock in the form of restricted stock units as compensation for serving on the company’s board and its committees. Each RSU converts into one share when it vests on January 4, 2027. After this award, he holds 30,847 shares directly.
RASTETTER WILLIAM H reported acquisition or exercise transactions in this Form 4 filing.
Dare Bioscience director William H. Rastetter received an equity grant of 38,862 restricted stock units (RSUs). The RSUs were granted in lieu of cash compensation for his service on the board of directors and its committees, at a stated price of $0.00 per share. Each RSU represents a contingent right to receive one share of common stock upon vesting, which occurs on January 4, 2027. Following this grant, he directly holds 39,721 shares of Dare Bioscience common stock.
Steele Robin Joan reported acquisition or exercise transactions in this Form 4 filing.
Dare Bioscience director Robin Joan Steele received an equity grant instead of cash fees for board service. She was awarded 26,540 restricted stock units, each representing one share of common stock when vested, at a stated price of $0.00 per unit. Following this grant, she directly holds 47,055 shares, including the new RSUs. The RSUs vest on January 4, 2027, aligning her compensation more closely with Dare Bioscience’s long-term share performance.
Dare Bioscience director William H. Rastetter received a grant of stock options for 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or immediately before the company’s first annual shareholder meeting after the grant date, subject to his continued board service. The options also become fully exercisable upon a change in control of Dare Bioscience.
Dare Bioscience director Susan L. Kelley received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036. Following this award, she holds 10,000 stock options directly from this grant.
The option will vest in full on the earlier of the first anniversary of the grant date or immediately before the company’s first annual stockholders’ meeting after the grant, as long as she continues serving as a director. It will also become fully exercisable upon a change in control of Dare Bioscience.
Dare Bioscience, Inc. director Robin Joan Steele received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036.
The option will vest in full on the earlier of the first anniversary of the June 11, 2026 grant date or immediately prior to the company’s first annual meeting of stockholders occurring after that date, subject to Steele’s continued service as a director. The option also becomes fully exercisable upon a change in control of the company. Following this grant, Steele holds 10,000 stock options directly.
Dare Bioscience, Inc. director Gregory W. Matz received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or immediately before the first annual stockholder meeting after the grant date, subject to his continued board service, and become fully exercisable upon a change in control.
Dare Bioscience, Inc. director Jessica D. Grossman received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036.
According to the terms, the option will vest in full on the earlier of the first anniversary of the grant date or immediately before the company’s first annual stockholder meeting after the grant date, as long as she continues serving as a director. The options also become fully exercisable upon a change in control of the company. Following this grant, she holds 10,000 stock options directly.
Dare Bioscience director and CEO Sabrina Martucci Johnson reported an acquisition of preferred stock and warrants tied to a Regulation A unit purchase. She subscribed on February 18, 2026 to purchase 10,800 Investor Units at $5 per Unit, with issuance to occur when the company accepts her subscription.
Each Unit includes one share of Series A Convertible Preferred Stock, initially convertible into two shares of common stock, plus two warrants, each to purchase one share of common stock. The preferred stock is perpetual, while the warrants become exercisable any time after issuance and expire 36 months after issuance, giving her long-dated, equity-linked exposure to the company.
Dare Bioscience, Inc. reported that Chief Executive Officer and director Sabrina Martucci Johnson received an employee stock option grant covering 172,000 shares of common stock on January 30, 2026. The option has an exercise price of $1.81 per share and was granted at a price of $0 per option.
The option vests in 48 equal monthly installments, beginning on the one-month anniversary of the grant date, as long as she continues to provide service to the company. After this grant, she directly holds 172,000 such derivative securities.
Dare Bioscience, Inc. reported that its Chief Accounting Officer, MarDee Haring-Layton, received an employee stock option grant. The award covers 49,000 options to purchase common stock at an exercise price of $1.81 per share, granted on January 30, 2026.
The option vests in 48 equal monthly installments starting one month after the grant date, conditioned on her continuous service with the company. Following this grant, she holds 49,000 derivative securities directly in the form of these stock options.